市場調查報告書
商品編碼
1408046
全球 PCR 技術市場評估:按產品、技術、應用、最終用戶、地區、機會、預測(2017-2031 年)Global PCR Technologies Market Assessment, By Product, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球PCR技術市場規模預計到2023年將達到150.5億美元,到2031年將達到297.5億美元,2024-2031年預測期間複合年增長率為8.89%。我是。 分子生物學、生命科學和生物技術領域的市場正在快速成長。 由於PCR在臨床疾病診斷和基因/分子檢測中的使用越來越多,市場正在擴大。 近年來,需要PCR技術進行診斷的肝炎、流感、HIV感染和COVID-19等傳染病的盛行率不斷上升,推動了全球PCR技術市場的需求。
數位 PCR (dPCR) 和即時 PCR (qPCR) 等 PCR 技術的進步帶來了試劑消耗更低、工作流程自動化以及更高的重現性和準確性等優勢,推動了 PCR 技術的採用。推動市場成長。 新興國家市場滲透率的提高和市場上有吸引力的機會正在導致融資和投資的增加。 隨著投資者和市場參與者興趣的增加,供給和需求都顯著增加。 此外,政府對研發的支持也進一步促進了市場的發展。 然而,PCR設備的高成本、PCR技術的技術限制以及缺乏熟練的專業人員來執行協議是市場的主要限制因素。
肝炎、流感和愛滋病毒等傳染病患者病率的增加是 PCR 技術市場的關鍵驅動因素。 傳染病和遺傳性疾病的增加導致對 PCR 技術的需求增加,因為它在這些疾病的診斷和監測中發揮重要作用。 PCR 廣泛用於檢測各種傳染原,包括病毒、細菌和真菌,使其成為傳染病管理的重要工具。 PCR技術也用於檢測導致遺傳性疾病的基因異常,進一步推動市場成長。
根據世界衛生組織的數據,截至 2022 年底,約有 3,900 萬人感染愛滋病毒,其中包括約 150 萬 0 至 14 歲的兒童。 季節性冬季流感可感染高達 20% 的人口並導致大量死亡。 根據世界衛生組織的數據,與季節性流感相關的呼吸道疾病每年導致全球 65 萬人死亡。
PCR技術在臨床診斷領域具有多種實際應用,近年來隨著研究和開發的增加,PCR應用顯著擴展。 PCR技術廣泛用於COVID-19診斷,推動市場需求。 PCR 技術的顯著應用包括廣譜病原體檢測、新興傳染病的評估和監測、生物威脅的早期檢測以及抗菌素抗藥性分析。 市場參與者正在針對 PCR 技術的新應用推出創新產品。
試劑和消耗品領域預計將在預測期內快速成長。 PCR檢測所使用的設備是一次性投資,而試劑和耗材是重複消耗和購買的,這使其成為關鍵的收入驅動力。 引子、聚合□、核甘酸、反應緩衝液等試劑,以及孔板、吸頭等耗材,在每次PCR過程中都會消耗殆盡,需要在下一次檢測時重新填充,很難上市,我們正在獲取經常性收入。
北美在全球 PCR 市場中佔據主導地位,其中美國和加拿大佔據最大的市場份額。 該地區的優勢源自於廣泛的研究基礎設施和完善的監管框架等因素,可加快新療法的批准。 該地區主要製藥和生物技術公司的存在正在推動 PCR 技術的開發和採用。 此外,北美在 PCR 研究和開發方面吸引了大量投資,從而可以建立最先進的設施並獲得先進技術。
本報告研究和分析了全球PCR技術市場,提供市場規模和預測、市場動態、主要公司趨勢和展望等。
Global PCR technologies market size was valued at USD 15.05 billion in 2023, and is expected to reach USD 29.75 billion in 2031, with a CAGR of 8.89% for the forecast period between 2024 and 2031F. The Polymerase Chain Reaction technologies market is a rapidly growing field in molecular biology, life sciences, and biotechnology. The PCR technologies market is expanding owing to the increasing application of PCR in clinical disease diagnosis and genetic and molecular testing. The prevalence of infectious diseases like hepatitis, influenza, HIV infection, and COVID-19 infection which require PCR techniques for diagnosis, have been on the rise in recent years, driving demand in the global PCR technologies market.
Advancements in PCR techniques, such as digital PCR (dPCR) and real-time PCR (qPCR), offer benefits like low reagent consumption, automation of workflow, and greater reproducibility and precision, which are encouraging the adoption of PCR technologies, further fueling the market growth. Growing market penetration in emerging countries and attractive opportunities in the PCR technologies market have led to increased funding and investments. With increasing interest from investors and market players, the demand and supply both are significantly increasing. Additionally, government support for research and development is further encouraging market development. However, the high cost of PCR instruments, technical limitations of PCR technology, and lack of skilled professionals to perform the protocols are major restraints for the global PCR technologies market.
In November 2023, QIAGEN announced the launch of three new kits (QIAcuity Mycoplasma Quant Kit, QIAcuity OneStep Advanced EG Kit, and QIAcuity Mericon Food Testing Kits) for using them with its QIAcuity systems. The launch has a part where major new software updates are designed to expand the portfolio of applications for the use of dPCR technology in areas like cell and gene therapies, quantification of DNA and RNA, as well as food and pharmaceutical safety.
The increasing prevalence of infectious diseases like hepatitis, influenza, HIV is a significant driver for the PCR technologies market. The rise in infectious diseases and genetic diseases has led to a growing demand for PCR technologies, as they play a crucial role in the diagnosis and monitoring of these diseases. PCR is widely used in the detection of various infectious agents, including viruses, bacteria, and fungi, making it an indispensable tool in infectious disease management. PCR technologies are also used in the detection of genetic abnormalities causing genetic diseases, further fueling the market for growth.
According to WHO, about 39.0 million people were living with HIV at the end of 2022, including about 1.5 million children within the age group of 0 to 14 years. Seasonal influenza throughout the winter can infect up to 20% of the population and result in significant death. According to WHO data, respiratory illnesses associated with seasonal influenza causes up to 650,000 deaths globally each year.
PCR technology has several practical applications in the field of clinical diagnosis and in recent years, with increasing research and development, a significant expansion of PCR applications has been observed. PCR technology has been extensively utilized for COVID-19 diagnosis, driving demand in the market. Several notable applications of PCR technologies include broad-spectrum pathogen detection, assessment and surveillance of emerging infections, early detection of biological threat agents, and antimicrobial resistance analysis. Market players are coming up with innovative products for emerging applications of PCR technologies. In August 2022, GenScript USA Inc. launched a monkeypox virus PCR test kit, which was developed in partnership with Anbio Biotechnology. The kit was developed to address the monkeypox public health emergency in the United States.
Reagents and consumables segments are expected to grow at a fast rate in the forecasted period. The instruments used for PCR tests are one-time investments while the reagents and consumables are repeatedly consumed and purchased, which drives major revenue. Reagents like primers, polymerase, nucleotides, reaction buffers, and consumables like well plates and pipette tips are consumed completely in each PCR process and need to be refilled for the next test, drawing reoccurring revenue in the market.
North America dominates the global PCR market, with the United States and Canada holding largest market shares. The region's dominance is attributed to several factors, including extensive research infrastructure and a well-established regulatory framework that expedites approvals for new therapies. The presence of major pharmaceutical and biotechnology companies in the region has driven the development and adoption of PCR technologies. Additionally, North America has attracted significant investments in PCR research and development, enabling the establishment of state-of-the-art facilities and access to advanced technologies.
The market landscape for PCR technologies is growing with several key players contributing to its development and commercialization. The key players in this market include Bio-Rad Laboratories Inc., Merck KGaA, QIAGEN and others. These companies are involved in various growth strategies, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions to enhance their presence.
In September 2023, Bio-Rad Laboratories, Inc. announced the launch of two new PCR instruments named PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers. PTC Tempo 48/48 and PTC Tempo 384 Thermal Cyclers are a novel addition to Bio-Rad Laboratories' portfolio of conventional PCR instruments. PTC Tempo 48/48 has the unique feature of two separate compartments with manual lids which allows two protocols to run simultaneously. The launch aims to support PCR applications in basic and translational research, process development, and quality control.
All segments will be provided for all regions and countries covered:
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.